NI201000071A - Una vacuna multicomponente o monocompon - Google Patents
Una vacuna multicomponente o monocomponInfo
- Publication number
- NI201000071A NI201000071A NI201000071A NI201000071A NI201000071A NI 201000071 A NI201000071 A NI 201000071A NI 201000071 A NI201000071 A NI 201000071A NI 201000071 A NI201000071 A NI 201000071A NI 201000071 A NI201000071 A NI 201000071A
- Authority
- NI
- Nicaragua
- Prior art keywords
- vaccine
- cruzi
- immunogenic
- immunogenic portion
- multicomponent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El objeto principal de la presente invención es una vacuna contra la enfermedad de Chagas, capaz de estimular la respuesta inmune contra el factor de virulencia trans-sialidasa del parásito Trvpanosoma cruzi, caracterizada dicha vacuna porque comprende una vacuna multicomponente para la enfermedad del Chagas (tripanosomiasis americana) caracterizada porque comprende: (a) una porción inmunógenica conformada por uno o mas polipéptidos recombinantes o sintéticos, o fracciones de ellos, y (b) uno o más polinucleótidos que comprenden a las regiones que codifican a uno o más polipéptidos inmunogénicos, ambas porciones para los derivados de los Trypanosoma cruzi ( es decir de un T. Cruzi y/o una región conservada común a varios de ellos) donde la administración de dicha vacuna protege de la infección del parásito, lo elimina o atenúa las consecuencias clínicas de dicha infección. Otro objeto de la presente invención es una vacuna monocomponente para la enfermedad del Chagas que comprende al menos un componente seleccionado entre una porción inmunógenica conformada por uno o más polipéptidos recombinantes o sintéticos, o fracciones de ellos y un grupo de polinucleótidos que comprenden a las regiones que codifican a uno o más polipéptidos inmunogénico derivados de los Trypanosoma cruzi ( es decir de un T. Cruzi y/o una región conservada común a varios de ellos), donde la porción inmunógenica o el grupo de polinucleótido estimula una respuesta de anticuerpos, de células T CD4+ sesgadas Th 1 o T CD8+ contra el Tripanosoma cruzi. También se incluyen en la presente invención las composiciones farmacéuticas que contienen dichas vacunas multicomponentes y monocomponentes, procedimientos para la obtención de la porción inmunogena de dichas vacunas y el acido nucleico utilizado en dicho procedimiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP070104827A AR064593A1 (es) | 2007-10-31 | 2007-10-31 | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201000071A true NI201000071A (es) | 2010-11-10 |
Family
ID=40591558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201000071A NI201000071A (es) | 2007-10-31 | 2010-04-26 | Una vacuna multicomponente o monocompon |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8900598B2 (es) |
| EP (1) | EP2206513B1 (es) |
| AR (1) | AR064593A1 (es) |
| BR (1) | BRPI0805753A2 (es) |
| CA (1) | CA2702534C (es) |
| CO (1) | CO6280407A2 (es) |
| CR (1) | CR11334A (es) |
| DO (1) | DOP2010000083A (es) |
| EC (1) | ECSP10010055A (es) |
| ES (1) | ES2569943T3 (es) |
| GT (1) | GT201000066A (es) |
| HN (1) | HN2010000750A (es) |
| MX (1) | MX2010004626A (es) |
| NI (1) | NI201000071A (es) |
| PA (1) | PA8816401A1 (es) |
| PE (2) | PE20091161A1 (es) |
| UY (1) | UY31451A1 (es) |
| WO (1) | WO2009056965A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR064593A1 (es) * | 2007-10-31 | 2009-04-15 | Baeremaecker Barros Carlos De | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
| WO2011031317A2 (en) * | 2009-09-10 | 2011-03-17 | The Board Of Regents Of The University Of Texas System | Vaccine for control of trypanosoma cruzi infection and chagas disease |
| BR112014001086A2 (pt) | 2011-07-21 | 2017-02-21 | Consejo Superior De Investig Cientificas/Csic | molécula quimérica útil na imunoterapia contra a leishmaniose, a qual compreende um fragmento da proteína pfr1 de leishmania infantum com epítopos específicos imunodominantes |
| US10279023B2 (en) | 2013-09-24 | 2019-05-07 | Board Of Regents, The University Of Texas System | Mucin-associated surface protein as a vaccine against chagas disease |
| US9566320B2 (en) | 2013-09-24 | 2017-02-14 | The Board Of Regents Of The University Of Texas System | Mucin-associated surface protein as vaccine against Chagas disease |
| BR112017028052A2 (pt) * | 2015-06-23 | 2018-09-11 | Epivax Inc | peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina |
| BR102021010469A2 (pt) * | 2021-05-28 | 2022-12-13 | Fundação Oswaldo Cruz | Proteína quimérica recombinante, seu uso, e, composição |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3937593A (en) | 1992-03-25 | 1993-10-21 | New York University | Trans-sialidase and methods of use and making thereof |
| US6875584B1 (en) * | 1999-03-02 | 2005-04-05 | University Of Georgia Research Foundation, Inc. | Prophylactic and therapeutic immunization against protozoan infection and disease |
| US7060676B2 (en) * | 1999-12-20 | 2006-06-13 | Trustees Of Tufts College | T. cruzi-derived neurotrophic agents and methods of use therefor |
| US7780969B2 (en) * | 2005-07-15 | 2010-08-24 | University Of Georgia Research Foundation, Inc. | Trypanosoma cruzi proteome compositions and methods |
| US9028844B2 (en) | 2006-03-17 | 2015-05-12 | Vib Vzw | Vaccine against Trypanosoma cruzi infection |
| AR064593A1 (es) * | 2007-10-31 | 2009-04-15 | Baeremaecker Barros Carlos De | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
-
2007
- 2007-10-31 AR ARP070104827A patent/AR064593A1/es unknown
-
2008
- 2008-10-30 MX MX2010004626A patent/MX2010004626A/es active IP Right Grant
- 2008-10-30 WO PCT/IB2008/002923 patent/WO2009056965A2/es not_active Ceased
- 2008-10-30 CA CA2702534A patent/CA2702534C/en not_active Expired - Fee Related
- 2008-10-30 ES ES08844056.5T patent/ES2569943T3/es active Active
- 2008-10-30 PE PE2008001858A patent/PE20091161A1/es not_active Application Discontinuation
- 2008-10-30 PE PE2013002770A patent/PE20140520A1/es active IP Right Grant
- 2008-10-30 EP EP08844056.5A patent/EP2206513B1/en not_active Not-in-force
- 2008-10-30 US US12/740,393 patent/US8900598B2/en not_active Expired - Fee Related
- 2008-10-31 UY UY31451A patent/UY31451A1/es not_active Application Discontinuation
- 2008-10-31 BR BRPI0805753-2A patent/BRPI0805753A2/pt not_active Application Discontinuation
-
2009
- 2009-02-19 PA PA20098816401A patent/PA8816401A1/es unknown
-
2010
- 2010-03-15 DO DO2010000083A patent/DOP2010000083A/es unknown
- 2010-03-23 GT GT201000066A patent/GT201000066A/es unknown
- 2010-03-24 CR CR11334A patent/CR11334A/es unknown
- 2010-03-26 EC EC2010010055A patent/ECSP10010055A/es unknown
- 2010-04-21 HN HN2010000750A patent/HN2010000750A/es unknown
- 2010-04-26 NI NI201000071A patent/NI201000071A/es unknown
- 2010-05-18 CO CO10058905A patent/CO6280407A2/es unknown
-
2014
- 2014-10-31 US US14/529,454 patent/US9662378B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 US US15/492,365 patent/US10213500B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2569943T3 (es) | 2016-05-13 |
| DOP2010000083A (es) | 2010-07-15 |
| GT201000066A (es) | 2012-04-03 |
| EP2206513B1 (en) | 2016-02-17 |
| UY31451A1 (es) | 2009-05-29 |
| US20170290896A1 (en) | 2017-10-12 |
| US9662378B2 (en) | 2017-05-30 |
| CA2702534A1 (en) | 2009-05-07 |
| US8900598B2 (en) | 2014-12-02 |
| PA8816401A1 (es) | 2009-09-17 |
| AR064593A1 (es) | 2009-04-15 |
| US20100297186A1 (en) | 2010-11-25 |
| CO6280407A2 (es) | 2011-05-20 |
| WO2009056965A3 (es) | 2009-07-23 |
| PE20091161A1 (es) | 2009-08-28 |
| US20150056243A1 (en) | 2015-02-26 |
| HN2010000750A (es) | 2013-08-19 |
| EP2206513A2 (en) | 2010-07-14 |
| CA2702534C (en) | 2016-10-18 |
| PE20140520A1 (es) | 2014-05-05 |
| US10213500B2 (en) | 2019-02-26 |
| MX2010004626A (es) | 2010-10-04 |
| WO2009056965A2 (es) | 2009-05-07 |
| CR11334A (es) | 2010-05-26 |
| BRPI0805753A2 (pt) | 2012-04-17 |
| ECSP10010055A (es) | 2010-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201000071A (es) | Una vacuna multicomponente o monocompon | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
| ECSP21023398A (es) | Dosis unitaria de vacuna contra el dengue y administración de esta | |
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| MX2019007119A (es) | Preparado oral del activador de glucocinasa y preparacion del mismo. | |
| BR112012005225B8 (pt) | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente | |
| BR112018017031A2 (pt) | formulações de antagonista de il-6 e usos das mesmas | |
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| BR112014001409A2 (pt) | métodos e composições para vacinação contra staphylococcus aureus | |
| MX2018015361A (es) | Formulacion de vacuna contra el vih. | |
| BR112013026661A2 (pt) | método de entrega de vacina | |
| DOP2010000188A (es) | Una vacuna de vih que comprende una proteina y un agente estabilizador | |
| MX2015011487A (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
| SG195115A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection | |
| BR112014017141A2 (pt) | método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada | |
| MX2015013115A (es) | Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue. | |
| BR112018007870A2 (pt) | composição imunogênica, método para a preparação de uma composição imunogênica, composição farmacêutica, vacina, método para estimular uma resposta imune em um paciente | |
| Manappallil | Ischemic stroke following Dengue fever: A case report | |
| CO6280495A2 (es) | Vacuna que contiene un extracto de proteina ribosoma (rpe) y opcionalmente un adyuvante que estimula las th1 | |
| CO2022007006A2 (es) | Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar | |
| BRPI0512393A (pt) | vacinação de jaritataca e/ou mangusto contra raiva | |
| BR112017002212A2 (pt) | peptídeo derivado de cdca1 e vacina contendo o mesmo |